



Hundredth Legislature - Second Session - 2008
Introducer's Statement of Intent
LB 713

Chairperson: Joel Johnson
Committee: Health and Human Services
Date of Hearing: January 23, 2008

The following constitutes the reasons for this bill and the purposes which are sought to be accomplished thereby:

LB 713 prohibits an individual licensed to practice medicine and surgery or osteopathic medicine and surgery from administering phosphatidylcholine or sodium deoxycholate, or any combination of these substances, by subcutaneous injection for the purposes of eliminating or reducing localized fat accumulation, *unless* the United States Food and Drug Administration (FDA) approves the use of these substances for this purpose.

The bill prohibits the use of a substance commonly referred to as lipodissolve (among other terms) for fat reduction until the procedure is approved by the FDA.

The bill becomes operative on December 1, 2008, the same date the Medicine and Surgery Practice Act becomes operative.

The bill protects Nebraska citizens from a medical procedure that has not been proven to be safe or effective. The FDA will not grant its approval until thorough testing and research has been completed.

Principal Introducer:

Senator Rich Pahls